EXTRACORPOREAL LIVER ASSIST FOR PIGS WITH DRUG INDUCED FULMINANT HEPATIC FAILURE USING A PACKED-BED TYPE BIO-ARTIFICIAL LIVER

ASAIO Journal ◽  
2003 ◽  
Vol 49 (2) ◽  
pp. 210
Author(s):  
K Yanagi ◽  
N Umamoto ◽  
N Ohshima
2010 ◽  
Vol 68 ◽  
pp. 467-467
Author(s):  
M Corno ◽  
E Bonanomi ◽  
I Pellicioli ◽  
A Tartufari ◽  
V Corno ◽  
...  

1994 ◽  
Vol 28 (10) ◽  
pp. 1159-1161 ◽  
Author(s):  
Preston P. Purdum ◽  
Stacey L. Shelden ◽  
John W. Boyd ◽  
Mitchell L. Shiffman

OBJECTIVE: To report oxaprozin-induced fulminant hepatic failure. CASE SUMMARY: A 56-year-old woman was admitted with fulminant hepatic failure. Work-up for potential etiologies was negative except for the use of oxaprozin for the preceding two months. Results of premortem liver biopsy were consistent with drug-induced hepatic injury similar to that previously reported with diclofenac. DISCUSSION: Although the literature describes elevation in hepatic transaminase concentrations associated with oxaprozin, fulminant hepatic failure has not been described previously. CONCLUSIONS: Elevations in hepatic transaminase concentrations and now fulminant hepatic failure have been shown to occur with oxaprozin, as previously seen with other nonsteroidal antiinflammatory drugs (NSAIDs). Transaminitis is a known adverse effect of NSAID use, but is usually mild and reversible with discontinuation of drug. Transaminitis may be more likely to occur in the elderly, in patients receiving concurrent potentially hepatotoxic medications, and possibly with the newer long-acting NSAIDs. The existence of fulminant hepatitis, although rare, supports the need for monitoring liver function enzymes during NSAID therapy.


2012 ◽  
Vol 30 (2) ◽  
pp. 179-183 ◽  
Author(s):  
Suraj J Patel ◽  
Jack M Milwid ◽  
Kevin R King ◽  
Stefan Bohr ◽  
Arvin Iracheta-Vellve ◽  
...  

ASAIO Journal ◽  
1996 ◽  
Vol 42 (3) ◽  
pp. 233-235
Author(s):  
KAZUFUMI OKAMOTO ◽  
MITSURO KUROSE ◽  
YOSHITOMO IKUTA ◽  
KENICHI OGATA ◽  
TOSHIKAZU HARADA ◽  
...  

2002 ◽  
Vol 6 (3) ◽  
pp. 208-212 ◽  
Author(s):  
Masakazu Nitta ◽  
Hiroyuki Hirasawa ◽  
Shigeto Oda ◽  
Hidetoshi Shiga ◽  
Kazuya Nakanishi ◽  
...  

2005 ◽  
Vol 39 (10) ◽  
pp. 1737-1740 ◽  
Author(s):  
şahin Çoban ◽  
Bilge Ceydilek ◽  
Fuat Ekiz ◽  
Esra Erden ◽  
İrfan Soykan

OBJECTIVE: To report a case of possible levofloxacin-induced acute fulminant hepatic failure. CASE SUMMARY: An unconscious 55-year-old woman was hospitalized with the diagnosis of hepatic encephalopathy. The patient had received levofloxacin 500 mg daily for 10 days because of an upper respiratory infection. Her past medical history revealed hepatitis B surface antigen positivity as an asymptomatic hepatitis B virus carrier for 10 years. After hospitalization, treatment included plasmapheresis and supportive care. The patient's consciousness improved on the second day of treatment. Other etiologies of fulminant hepatic failure were ruled out, suggesting levofloxacin-induced fulminant hepatic failure. Although the patient received supportive treatment, her condition gradually deteriorated and she died 12 weeks after admission to our hospital. An objective causality assessment revealed that the adverse event was possibly related to levofloxacin. DISCUSSION: Levofloxacin is widely used because of its broad spectrum of antimicrobial activity. As of August 9, 2005, to our knowledge, only one case of fulminant hepatic failure in relation to levofloxacin has previously been published. We believe that, in our patient, the relationship between levofloxacin and her illness is clear because of the negative results in the etiological studies, the short time between the drug's administration and the development of disease, and the pathologic findings suggestive of drug-induced hepatitis. CONCLUSIONS: Clinicians should be aware of the possibility of severe hepatic injury associated with levofloxacin when prescribing this drug.


Sign in / Sign up

Export Citation Format

Share Document